

Former Policy #	New Policy #	Policy Name	Type of Change	Brief Description of Policy Change	Reason for Changes
NEW	ECG 3185	Modeyso (dordaviprone)	Positive	On August 6, 2025, the Food and Drug Administration granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals, Inc.), a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.	New FDA Drug/Indication
NEW	ECG 3186	Hernexeos (zongertinib)	Positive	On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.	New FDA Drug/Indication
UM ONC_1311	ECG 3176	Lonsurf (trifluridine/tipiracil)	No clinical change	1) Converted to new Evolent policy template 2) Updated indication section 3) Updated maximum dosage form quantities in exclusion criteria 4) Updated references	Annual Review
UM ONC_1382	ECG 3177	Eculizumab Products	Positive	1) Converted to new Evolent policy template 2) Updated verbiage in purpose statement 3) Added new biosimilar "Bkernv (eculizumab-aeeb)" to policy 4) Updated references	Annual Review
UM ONC_1433	ECG 3178	Jemperli (dostarlimab-gxly)	Positive	1) Converted to new Evolent policy template 2) Updated endometrial cancer section to allow use with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, with primary advanced or recurrent disease 3) Updated indication section 4) Updated references	Annual Review
UM ONC_1462	ECG 3179	Opdualag (nivolumab and relatlimab-rmbw)	No clinical change	1) Converted to new Evolent policy template 2) Updated indication section 3) Updated exclusion criteria 4) Updated references	Annual Review
UM ONC_1482	ECG 3180	Elrexfio (elranatamab-bcmm)	No clinical change	1) Converted to new Evolent policy template 2) Updated references	Annual Review
UM ONC_1483	ECG 3181	Talvey (talquetamab-tgvs)	No clinical change	1) Converted to new Evolent policy template 2) Updated references	Annual Review
UM ONC_1484	ECG 3182	Vanflyta (quizartinib)	No clinical change	1) Converted to new Evolent policy template 2) Updated indication section 3) Updated maximum dosage form quantities in exclusion criteria 4) Updated references	Annual Review
UM ONC_1507	ECG 3183	Tecelra (afamitresgene autoleucel)	No clinical change	1) Converted to new Evolent policy template 2) Updated indication section 3) Updated references	Annual Review
UM ONC_1508	ECG 3184	Voranigo (vorasidenib)	No clinical change	1) Converted to new Evolent policy template 2) Updated maximum dosage form quantities in exclusion criteria 3) Updated exclusion criteria 4) Updated references	Annual Review
UM ONC_1219	ECG 3187	Jevtana (cabazitaxel)	Positive	1) Converted to new Evolent policy template 2) Added new HCPC code 3) Updated references	Other
ECG 3033	ECG 3033	Clolar (clofarabine)	No clinical change	Moved medication to "ECG 3039 for Generic Drugs" since generic formulations of the drug are available, and will archive policy	Other
ECG 3039	ECG 3039	Generic Drugs	No clinical change	1) Added "Clolar (clofarabine)", "Beizray (docetaxel)", and "Docivyx (docetaxel)" to the list of drugs in policy 2) Replaced "Nolvadex (tamoxifen)" with "Soltamox (tamoxifen)" on the list of drugs in policy since Nolvadex is no longer commercially available in the US	Other
ECG 3153	ECG 3153	Zusduri (mitomycin intravesical solution)	Positive	Updated exclusion criteria to exclude members with prior intravesical chemotherapy within the prior two years (except for a single dose of intravesical chemotherapy immediately after any previous TURBT) and/or had BCG treatment within the previous year, as per study.	Other
UM ONC_1376		Oxbryta (voxelotor)	Positive	Drug withdrawal	Archive policy